ijms-logo

Journal Browser

Journal Browser

Synthesis, Activity and Mechanism of Enzyme Inhibitors

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1324

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemistry, Siedlce University of Natural Sciences and Humanities, 3-go Maja 54, 08-110 Siedlce, Poland
Interests: organic compounds; heterocycles; natural derivatives; biological activity; enzyme inhibition; anticancer activity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Enzymes are very effective biological catalysts that accelerate almost all metabolic reactions in living organisms. They are used as tools for studying enzymes and as well as for the design of new medicine drugs for treating certain disorders. Moreover, enzyme inhibitors and activators that modulate the velocity of enzymatic reactions play an important role in the regulation of metabolism. The suppression or activation of the enzyme activity is the result of the binding of inhibitor/activator to the enzyme molecule that arrests or accelerates catalytic reaction. Because enzymes catalyze most part of chemical reactions in living organisms, enzyme inhibitors play an important role in the development of different sciences (biochemistry, physiology, pharmacy, agriculture, ecology) as well as technologies (production of pharmaceutical drugs, insecticides, pesticides, chemical weapons, etc.). For this reason, there is growing interest in the search for new molecules as potential inhibitors or activators of various enzymes.

In this Special Issue, we welcome reviews, original research articles, and short communications that focus on advances related to the design, synthesis, and identification of new synthetic and natural enzyme inhibitors and their mechanism of action that can be used for the design of various types of pharmacological drugs and natural inhibitors as a plausible source for the design of future drugs.

Dr. Mariusz Mojzych
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • organic compounds
  • heterocycles
  • enzymes inhibition
  • mechanism of action
  • natural products
  • inhibitors
  • interaction with enzyme
  • kinetic studies of enzymatic reactions

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 1908 KiB  
Article
BAY-3827 and SBI-0206965: Potent AMPK Inhibitors That Paradoxically Increase Thr172 Phosphorylation
by Simon A. Hawley, Fiona M. Russell, Fiona A. Ross and D. Grahame Hardie
Int. J. Mol. Sci. 2024, 25(1), 453; https://doi.org/10.3390/ijms25010453 - 29 Dec 2023
Viewed by 1049
Abstract
AMP-activated protein kinase (AMPK) is the central component of a signalling pathway that senses energy stress and triggers a metabolic switch away from anabolic processes and towards catabolic processes. There has been a prolonged focus in the pharmaceutical industry on the development of [...] Read more.
AMP-activated protein kinase (AMPK) is the central component of a signalling pathway that senses energy stress and triggers a metabolic switch away from anabolic processes and towards catabolic processes. There has been a prolonged focus in the pharmaceutical industry on the development of AMPK-activating drugs for the treatment of metabolic disorders such as Type 2 diabetes and non-alcoholic fatty liver disease. However, recent findings suggest that AMPK inhibitors might be efficacious for treating certain cancers, especially lung adenocarcinomas, in which the PRKAA1 gene (encoding the α1 catalytic subunit isoform of AMPK) is often amplified. Here, we study two potent AMPK inhibitors, BAY-3827 and SBI-0206965. Despite not being closely related structurally, the treatment of cells with either drug unexpectedly caused increases in AMPK phosphorylation at the activating site, Thr172, even though the phosphorylation of several downstream targets in different subcellular compartments was completely inhibited. Surprisingly, the two inhibitors appear to promote Thr172 phosphorylation by different mechanisms: BAY-3827 primarily protects against Thr172 dephosphorylation, while SBI-0206965 also promotes phosphorylation by LKB1 at low concentrations, while increasing cellular AMP:ATP ratios at higher concentrations. Due to its greater potency and fewer off-target effects, BAY-3827 is now the inhibitor of choice for cell studies, although its low bioavailability may limit its use in vivo. Full article
(This article belongs to the Special Issue Synthesis, Activity and Mechanism of Enzyme Inhibitors)
Show Figures

Graphical abstract

Back to TopTop